Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of PF-07248144
NCT07423286Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of prifetrastat in breast cancer, sponsored by Pfizer. Primary endpoints: Total recovery of radioactivity in urine, feces and vomitus at 22 days and Metabolic profiling and identification of metabolites at 22 days. Started Oct 2025; status: completed.
02
Drugs
prifetrastat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07423286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423286.